The Mesenchymal Compartment in Myelodysplastic Syndrome: Its Role in the Pathogenesis of the Disorder and Its Therapeutic Targeting

Overview

Journal Front Oncol

Specialty Oncology

Date 2023 Feb 10

PMID 36761941

Authors

Charalampos G Pontikoglou

Angelos Matheakakis

Helen A Papadaki

Affiliations

Soon will be listed here.

Abstract

Myelodysplastic syndromes include a broad spectrum of malignant myeloid disorders that are characterized by dysplastic ineffective hematopoiesis, reduced peripheral blood cells counts and a high risk of progression to acute myeloid leukemia. The disease arises primarily because of accumulating chromosomal, genetic and epigenetic changes as well as immune-mediated alterations of the hematopoietic stem cells (HSCs). However, mounting evidence suggests that aberrations within the bone marrow microenvironment critically contribute to myelodysplastic syndrome (MDS) initiation and evolution by providing permissive cues that enable the abnormal HSCs to grow and eventually establish and propagate the disease. Mesenchymal stromal cells (MSCs) are crucial elements of the bone marrow microenvironment that play a key role in the regulation of HSCs by providing appropriate signals soluble factors and cell contact interactions. Given their hematopoiesis supporting capacity, it has been reasonable to investigate MSCs' potential involvement in MDS. This review discusses this issue by summarizing existing findings obtained by studies and murine disease models of MDS. Furthermore, the theoretical background of targeting the BM-MSCs in MDS is outlined and available therapeutic modalities are described.

Citing Articles

MSCs with upregulated lipid metabolism block hematopoietic stem cell differentiation via exosomal CTP-1A in MDS.

Yin C, Yan X, Ren J, Zhang C, Liu J, Wang Z Stem Cell Res Ther. 2025; 16(1):53.

PMID: 39920846 PMC: 11806692. DOI: 10.1186/s13287-025-04154-3.

Mesenchymal Stem Cells in Myelodysplastic Syndromes and Leukaemia.

Eroz I, Kakkar P, Lazar R, El-Jawhari J Biomedicines. 2024; 12(8).

PMID: 39200142 PMC: 11351218. DOI: 10.3390/biomedicines12081677.

References

Velasco-Hernandez T, Sawen P, Bryder D, Cammenga J . Potential Pitfalls of the Mx1-Cre System: Implications for Experimental Modeling of Normal and Malignant Hematopoiesis. Stem Cell Reports. 2016; 7(1):11-8. PMC: 4945592. DOI: 10.1016/j.stemcr.2016.06.002. View

Hu J, Meng F, Hu X, Huang L, Liu H, Liu Z . Iron overload regulate the cytokine of mesenchymal stromal cells through ROS/HIF-1α pathway in Myelodysplastic syndromes. Leuk Res. 2020; 93:106354. DOI: 10.1016/j.leukres.2020.106354. View

Lopez-Villar O, Garcia J, Sanchez-Guijo F, Robledo C, Villaron E, Hernandez-Campo P . Both expanded and uncultured mesenchymal stem cells from MDS patients are genomically abnormal, showing a specific genetic profile for the 5q- syndrome. Leukemia. 2009; 23(4):664-72. DOI: 10.1038/leu.2008.361. View

Antonelli A, Noort W, Jaques J, de Boer B, de Jong-Korlaar R, Brouwers-Vos A . Establishing human leukemia xenograft mouse models by implanting human bone marrow-like scaffold-based niches. Blood. 2016; 128(25):2949-2959. DOI: 10.1182/blood-2016-05-719021. View

Bhagat T, Chen S, Bartenstein M, Barlowe A, von Ahrens D, Choudhary G . Epigenetically Aberrant Stroma in MDS Propagates Disease via Wnt/β-Catenin Activation. Cancer Res. 2017; 77(18):4846-4857. PMC: 5600853. DOI: 10.1158/0008-5472.CAN-17-0282. View

Mian S, Bonnet D . Nature or Nurture? Role of the Bone Marrow Microenvironment in the Genesis and Maintenance of Myelodysplastic Syndromes. Cancers (Basel). 2021; 13(16). PMC: 8394536. DOI: 10.3390/cancers13164116. View

Kawabata K, Hayashi Y, Inoue D, Meguro H, Sakurai H, Fukuyama T . High expression of ABCG2 induced by EZH2 disruption has pivotal roles in MDS pathogenesis. Leukemia. 2017; 32(2):419-428. DOI: 10.1038/leu.2017.227. View

Chen S, Zambetti N, Bindels E, Kenswill K, Mylona A, Adisty N . Massive parallel RNA sequencing of highly purified mesenchymal elements in low-risk MDS reveals tissue-context-dependent activation of inflammatory programs. Leukemia. 2016; 30(9):1938-42. PMC: 5240018. DOI: 10.1038/leu.2016.91. View

Pavlaki K, Pontikoglou C, Demetriadou A, Batsali A, Damianaki A, Simantirakis E . Impaired proliferative potential of bone marrow mesenchymal stromal cells in patients with myelodysplastic syndromes is associated with abnormal WNT signaling pathway. Stem Cells Dev. 2014; 23(14):1568-81. DOI: 10.1089/scd.2013.0283. View

10.

Jann J, Mossner M, Riabov V, Altrock E, Schmitt N, Flach J . Bone marrow derived stromal cells from myelodysplastic syndromes are altered but not clonally mutated in vivo. Nat Commun. 2021; 12(1):6170. PMC: 8546146. DOI: 10.1038/s41467-021-26424-3. View

11.

Gattermann N . Iron overload in myelodysplastic syndromes (MDS). Int J Hematol. 2017; 107(1):55-63. DOI: 10.1007/s12185-017-2367-1. View

12.

Kouvidi E, Stratigi A, Batsali A, Mavroudi I, Mastrodemou S, Ximeri M . Cytogenetic evaluation of mesenchymal stem/stromal cells from patients with myelodysplastic syndromes at different time-points during ex vivo expansion. Leuk Res. 2016; 43:24-32. DOI: 10.1016/j.leukres.2016.02.007. View

13.

Krevvata M, Shan X, Zhou C, Dos Santos C, Habineza Ndikuyeze G, Secreto A . Cytokines increase engraftment of human acute myeloid leukemia cells in immunocompromised mice but not engraftment of human myelodysplastic syndrome cells. Haematologica. 2018; 103(6):959-971. PMC: 6058784. DOI: 10.3324/haematol.2017.183202. View

14.

Ades L, Itzykson R, Fenaux P . Myelodysplastic syndromes. Lancet. 2014; 383(9936):2239-52. DOI: 10.1016/S0140-6736(13)61901-7. View

15.

Medyouf H, Mossner M, Jann J, Nolte F, Raffel S, Herrmann C . Myelodysplastic cells in patients reprogram mesenchymal stromal cells to establish a transplantable stem cell niche disease unit. Cell Stem Cell. 2014; 14(6):824-37. DOI: 10.1016/j.stem.2014.02.014. View

16.

Pang Y, Geng S, Zhang H, Lai P, Liao P, Zeng L . Phenotype of mesenchymal stem cells from patients with myelodyplastic syndrome maybe partly modulated by decitabine. Oncol Lett. 2019; 18(5):4457-4466. PMC: 6781515. DOI: 10.3892/ol.2019.10788. View

17.

Wang Z, Tang X, Xu W, Cao Z, Sun L, Li W . The different immunoregulatory functions on dendritic cells between mesenchymal stem cells derived from bone marrow of patients with low-risk or high-risk myelodysplastic syndromes. PLoS One. 2013; 8(3):e57470. PMC: 3587596. DOI: 10.1371/journal.pone.0057470. View

18.

Weidner H, Baschant U, Lademann F, Ledesma Colunga M, Balaian E, Hofbauer C . Increased FGF-23 levels are linked to ineffective erythropoiesis and impaired bone mineralization in myelodysplastic syndromes. JCI Insight. 2020; 5(15). PMC: 7455070. DOI: 10.1172/jci.insight.137062. View

19.

Acar M, Kocherlakota K, Murphy M, Peyer J, Oguro H, Inra C . Deep imaging of bone marrow shows non-dividing stem cells are mainly perisinusoidal. Nature. 2015; 526(7571):126-30. PMC: 4850557. DOI: 10.1038/nature15250. View

20.

Huang J, Shimamura A . Clinical spectrum and molecular pathophysiology of Shwachman-Diamond syndrome. Curr Opin Hematol. 2010; 18(1):30-5. PMC: 3485416. DOI: 10.1097/MOH.0b013e32834114a5. View